on Galimedix, Inc.
Galimedix Announces Fall 2026 Conference Participation
Galimedix Therapeutics, Inc., a clinical-stage biotechnology company, has announced its participation in multiple investor, partnering, and scientific conferences in fall 2026. The company is focused on developing neuroprotective therapies for brain and eye diseases.
Key events include the LSX Congress USA in Boston, and the H.C. Wainwright Biotech on Tap in Munich. Additionally, Galimedix will present at the 26th Annual Biotech in Europe Forum in Basel and the BioFuture event in New York. The company will also attend BIO-Europe in Cologne.
In the scientific arena, Galimedix will participate in the 26th EURETINA Congress in Vienna and the American Academy of Ophthalmology Annual Meeting in New Orleans. They will present a poster at the Clinical Trials on Alzheimer's Disease Conference in Boston, focused on their Phase 2a study of GAL-101 salt.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news